Hawaii biologics regulations.

Who may administer PRP, exosomes and stem cells in Hawaii, and which agencies to check.

A physician at a desk reading regulatory documents

Who may administer biologics in Hawaii?

In Hawaii, only qualified and licensed medical professionals (MD/DO) are permitted to administer stem cell and other biologic therapies. This generally includes physicians, physician assistants, and nurse practitioners.

Official sources

Hawaii compliance guide.

FDA Compliance

The U.S. Food and Drug Administration (FDA) regulates biologics, particularly human cells, tissues, and cellular and tissue-based products (HCT/Ps), to ensure patient safety. Hawaii clinics should familiarize themselves with the FDA’s guidelines for HCT/Ps as well as the applicable federal requirements under 21 CFR Part 1271. Compliance involves ensuring proper labeling, handling, and oversight of biologics to meet FDA standards.

Hawaii State Regulations

Hawaii requires adherence to state-specific healthcare regulations, which can be found on the Hawaii Department of Health website. Providers in Hawaii must ensure their practices align with these state guidelines for biologics, which may have specific requirements for facility licensing and reporting.

Provider Qualifications

In Hawaii, only qualified and licensed medical professionals (MD/DO) are permitted to administer stem cell and other biologic therapies. This generally includes physicians, physician assistants, and nurse practitioners. Providers should consult the Hawaii Department of Commerce and Consumer Affairs - Professional and Vocational Licensing Division to verify qualification criteria, especially if pursuing licensing for new or advanced procedures involving biologics.

Patient Informed Consent

Before administering biologic treatments, Hawaii clinics must provide patients with a thorough informed consent form. This document should outline potential risks, benefits, and the experimental status of some therapies. It’s crucial for patients to understand these factors and confirm their agreement in writing prior to any procedure.

Additional Compliance Considerations

Pre-Treatment and Post-Treatment Protocols

Establishing clear protocols for pre-treatment evaluation and post-treatment follow-up helps in maintaining compliance and improving patient outcomes. Clinics are encouraged to standardize protocols for patient care, infection control, and procedure monitoring.

Standard Operating Procedures (SOPs)

Developing SOPs for the handling, storage, and administration of biologics is essential for maintaining compliance. Regularly review and update these procedures to reflect current best practices and regulatory requirements.

Medical Liability Insurance

Hawaii practitioners offering biologic therapies should ensure their medical liability insurance covers these treatments. Given the evolving nature of biologics, it’s wise to verify coverage terms regularly and make updates as necessary.

Marketing Compliance

Marketing materials for biologics in Hawaii must adhere to FDA and state advertising guidelines. Avoid exaggerated or unsupported claims, especially given the experimental aspects of many biologic treatments, to ensure transparency and compliance.

This guide is a general summary to help clinics understand compliance requirements for biologics in Hawaii. It is not legal advice. Regulations change; consult legal counsel and the agencies above before acting on it.

Hawaii: common questions.

Who can administer stem cells, PRP and exosomes in Hawaii?
In Hawaii, only qualified and licensed medical professionals (MD/DO) are permitted to administer stem cell and other biologic therapies. This generally includes physicians, physician assistants, and nurse practitioners. This is a general summary, not legal advice. Confirm with the state board.
Are stem cell and exosome therapies FDA-approved in Hawaii?
FDA rules are federal, so they apply in Hawaii as everywhere else. Exosome and stem cell therapies are not FDA-approved for therapeutic use, and PRP applications are considered off-label.
Do I need an IRB-approved study to offer biologics in Hawaii?
Investigational treatment belongs inside a reviewed study with proper informed consent. IRB review is not FDA authorisation: culture-expanded and other more-than-minimally-manipulated cell products generally need an IND before use in people.
How do I start offering biologics in Hawaii?
Start with the live webinar, then a discovery call and live training. After that we verify your Hawaii licence, protocol, product sourcing, consent process and advertising before you are listed for patient inquiries.

Practising in Hawaii? Start with the webinar.

Live on Zoom, Tuesdays at 12:00 PM ET. See how the model works before you commit to anything.